{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:45:00Z","timestamp":1777463100882,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Istanbul University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urolithiasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Potassium citrate is widely used as oral alkali therapy for the prevention of recurrent nephrolithiasis. Despite its long-standing clinical use, systematically collected real-world safety data remain limited. We performed a pharmacovigilance analysis to characterize adverse event reports associated with potassium citrate using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). FAERS reports submitted between 2014 and 2025 listing potassium citrate as the primary suspect drug were analyzed. Duplicate records were removed, and adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) at both the system organ class and standardized event term levels (preferred terms, PTs). Disproportionality analyses were conducted using reporting odds ratio, proportional reporting ratio, bayesian confidence propagation neural network, and multi-item gamma poisson shrinker methods. A total of 408 unique reports were included. Most reports involved adults and were physician-reported from the United States. Disproportionality analysis identified potential safety issues (signals), defined as drug event associations reported more frequently than expected in FAERS and therefore warranting further evaluation, although not establishing causality. The strongest associations involved product-related issues, laboratory investigations, and gastrointestinal disorders. When these potential safety issues were described using standardized MedDRA event terms most reflected formulation- and administration-related problems, including tablet residue in stool, abnormal solubility, swallowing difficulty, throat irritation, and foreign body sensations. Reports of rash were infrequent. This first FAERS-based analysis of potassium citrate highlights that most reported adverse events are related to formulation and administration characteristics rather than drug toxicity. These findings support the overall tolerability of potassium citrate while underscoring the importance of adherence, patient education, and formulation-specific considerations in clinical practice. As a spontaneous reporting system, FAERS is valuable for hypothesis generation, label expansion, and post-marketing surveillance, but it is not suitable for estimating the incidence or absolute risk of adverse events.<\/jats:p>","DOI":"10.1007\/s00240-026-01989-0","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:19:30Z","timestamp":1777382370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacovigilance analysis and real-world adverse event profile (safety signals and product-related issues) of potassium citrate: a US FDA adverse event reporting system (FAERS) based analysis"],"prefix":"10.1007","volume":"54","author":[{"given":"Rifat Burak","family":"Erg\u00fcl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail Taha","family":"G\u00fcrlek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasin","family":"Yitgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyda G\u00fcl","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F\u0131rat","family":"\u00d6zervarl\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar","family":"Turan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samed","family":"Verep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samet","family":"\u015eenel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arda","family":"Atar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muratcan","family":"Kiremit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Pietropaolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. \u0130lker","family":"G\u00f6k\u00e7e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Somani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kemal","family":"Sarica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzevat","family":"Tefik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"9","key":"1989_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00345-017-2008-6","volume":"35","author":"I Sorokin","year":"2017","unstructured":"Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y (2017) Epidemiology of stone disease across the world. World J Urol 35(9):1301\u20131320. https:\/\/doi.org\/10.1007\/s00345-017-2008-6","journal-title":"World J Urol"},{"issue":"5","key":"1989_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1046\/j.1523-1755.2003.00917.x","volume":"63","author":"KK Stamatelou Jr","year":"2003","unstructured":"Stamatelou KK, Francis ME, Jones CA, Nyberg LM Jr, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976\u20131994. Kidney Int 63(5):1817\u20131823. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00917.x","journal-title":"Kidney Int"},{"issue":"3","key":"1989_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000052367","volume":"37","author":"WL Strohmaier","year":"2000","unstructured":"Strohmaier WL (2000) Course of calcium stone disease without treatment. What can we expect? Eur Urol 37(3):339\u2013344. https:\/\/doi.org\/10.1159\/000052367","journal-title":"Eur Urol"},{"issue":"2","key":"1989_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40620-016-0283-8","volume":"30","author":"PM Ferraro","year":"2017","unstructured":"Ferraro PM, Curhan GC, D\u2019Addessi A, Gambaro G (2017) Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol 30(2):227\u2013233. https:\/\/doi.org\/10.1007\/s40620-016-0283-8","journal-title":"J Nephrol"},{"issue":"5","key":"1989_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00240-016-0938-x","volume":"45","author":"M Zhe","year":"2017","unstructured":"Zhe M, Hang Z (2017) Nephrolithiasis as a risk factor of chronic kidney disease: a meta-analysis of cohort studies with 4,770,691 participants. Urolithiasis 45(5):441\u2013448. https:\/\/doi.org\/10.1007\/s00240-016-0938-x","journal-title":"Urolithiasis"},{"issue":"2","key":"1989_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.juro.2016.12.135","volume":"198","author":"G Gambaro","year":"2017","unstructured":"Gambaro G, Croppi E, Bushinsky D, Jaeger P, Cupisti A, Ticinesi A, Mazzaferro S, D\u2019Addessi A, Ferraro PM (2017) The risk of chronic kidney disease associated with urolithiasis and its urological treatments: a review. J Urol 198(2):268\u2013273. https:\/\/doi.org\/10.1016\/j.juro.2016.12.135","journal-title":"J Urol"},{"key":"1989_CR7","doi-asserted-by":"publisher","unstructured":"Bao Y, Wei Q (2012) Cd004292. Water for preventing urinary stones. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd004292.pub3","DOI":"10.1002\/14651858.cd004292.pub3"},{"issue":"7","key":"1989_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.7326\/0003-4819-158-7-201304020-00005","volume":"158","author":"HA Fink","year":"2013","unstructured":"Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Ouellette J, Monga M (2013) Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 158(7):535\u2013543. https:\/\/doi.org\/10.7326\/0003-4819-158-7-201304020-00005","journal-title":"Ann Intern Med"},{"issue":"6","key":"1989_CR9","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/s0022-5347(01)68155-2","volume":"158","author":"B Ettinger","year":"1997","unstructured":"Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158(6):2069\u20132073. https:\/\/doi.org\/10.1016\/s0022-5347(01)68155-2","journal-title":"J Urol"},{"issue":"6","key":"1989_CR10","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/s0022-5347(17)35888-3","volume":"150","author":"P Barcelo","year":"1993","unstructured":"Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol doi 150(6):1761\u20131764. https:\/\/doi.org\/10.1016\/s0022-5347(17)35888-3","journal-title":"J Urol doi"},{"issue":"10","key":"1989_CR11","doi-asserted-by":"publisher","first-page":"CD010057","DOI":"10.1002\/14651858.CD010057.pub2","volume":"2015","author":"R Phillips","year":"2015","unstructured":"Phillips R, Hanchanale VS, Myatt A, Somani B, Nabi G, Biyani CS (2015) Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev 2015(10):CD010057. https:\/\/doi.org\/10.1002\/14651858.CD010057.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1989_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00240-015-0846-5","volume":"44","author":"JR Asplin","year":"2016","unstructured":"Asplin JR (2016) The management of patients with enteric hyperoxaluria. Urolithiasis doi 44(1):33\u201343. https:\/\/doi.org\/10.1007\/s00240-015-0846-5","journal-title":"Urolithiasis doi"},{"issue":"6","key":"1989_CR13","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/s0022-5347(17)36401-7","volume":"149","author":"CL Wabner","year":"1993","unstructured":"Wabner CL, Pak CY (1993) Effect of orange juice consumption on urinary stone risk factors. J Urol doi 149(6):1405\u20131408. https:\/\/doi.org\/10.1016\/s0022-5347(17)36401-7","journal-title":"J Urol doi"},{"key":"1989_CR14","volume-title":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025 ed","author":"Urology EAo","year":"2024","unstructured":"Urology EAo (2024) EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025 ed. EAU Guidelines Office, Arnhem, the Netherlands"},{"key":"1989_CR15","doi-asserted-by":"publisher","unstructured":"Williams JC Jr, Gambaro G, Rodgers A, Asplin J, Bonny O, Costa-Bauz\u00e1 A, Ferraro PM, Fogazzi G, Fuster DG, Goldfarb DS, Grases F (2021) Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis. ;49(1):1-6. https:\/\/doi.org\/10.1007\/s00240-020-01217-3","DOI":"10.1007\/s00240-020-01217-3"},{"key":"1989_CR16","unstructured":"Administration USFD (2025) FDA Adverse Event Reporting System (FAERS) Public Dashboard. https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers Accessed 2025-08-04 2025"},{"key":"1989_CR17","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Liu Y, Wu P, He X, Zhang Q (2022) Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol 13:862508. https:\/\/doi.org\/10.3389\/fphar.2022.862508","journal-title":"Front Pharmacol"},{"issue":"1","key":"1989_CR18","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","volume":"12","author":"M Guo","year":"2022","unstructured":"Guo M, Shu Y, Chen G, Li J, Li F (2022) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep 12(1):20601. https:\/\/doi.org\/10.1038\/s41598-022-23726-4","journal-title":"Sci Rep"},{"key":"1989_CR19","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Ran L, Liang Y, Zhang Y, An Z (2023) Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system. Front Pharmacol 14:1194545. https:\/\/doi.org\/10.3389\/fphar.2023.1194545","journal-title":"Front Pharmacol"},{"issue":"5","key":"1989_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B (2020) Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf 43(5):479\u2013487. https:\/\/doi.org\/10.1007\/s40264-020-00911-w","journal-title":"Drug Saf"},{"issue":"6","key":"1989_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol doi 72(6):905\u2013908. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04037.x","journal-title":"Br J Clin Pharmacol doi"},{"issue":"8","key":"1989_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1989_CR23","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","volume":"14","author":"Y Wu","year":"2023","unstructured":"Wu Y, Wei M, Zhang J (2023) A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib. Front Pharmacol 14:1200254. https:\/\/doi.org\/10.3389\/fphar.2023.1200254","journal-title":"Front Pharmacol"},{"issue":"7","key":"1989_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data Mining of the Public Version of the FDA Adverse Event Reporting System. Int J Med Sci 10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"issue":"6","key":"1989_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1989_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A De Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1989_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota K, Koide D, Hirai T (2004) Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf 13(6):387\u2013394. https:\/\/doi.org\/10.1002\/pds.964","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1989_CR28","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","volume":"13","author":"S Tang","year":"2022","unstructured":"Tang S, Wu Z, Xu L, Wen Q, Zhang X (2022) Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on FAERS. Front Pharmacol 13:970066. https:\/\/doi.org\/10.3389\/fphar.2022.970066","journal-title":"Front Pharmacol"},{"issue":"1","key":"1989_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40780-018-0109-z","volume":"4","author":"Y Noguchi","year":"2018","unstructured":"Noguchi Y, Katsuno H, Ueno A, Otsubo M, Yoshida A, Kanematsu Y et al (2018) Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database. J Pharm Health Care Sci 4(1):15. https:\/\/doi.org\/10.1186\/s40780-018-0109-z","journal-title":"J Pharm Health Care Sci"},{"key":"1989_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhou L, Shen Y, Zhou Q, Ji Y, Zhu H (2024) Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disord 346:223\u2013229. https:\/\/doi.org\/10.1016\/j.jad.2023.11.025","journal-title":"J Affect Disord"},{"issue":"6","key":"1989_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT (2002) Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf 25(6):381\u2013392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001","journal-title":"Drug Saf"},{"issue":"1","key":"1989_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1989_CR33","unstructured":"Administration USFD (2010) Urocit-K (potassium citrate) extended-release tablets: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/019071s012lbl.pdf Accessed"},{"issue":"1","key":"1989_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/003655900750016869","volume":"34","author":"C Jendle-Bengten","year":"2000","unstructured":"Jendle-Bengten C, Tiselius HG (2000) Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. Scand J Urol Nephrol 34(1):36\u201341. https:\/\/doi.org\/10.1080\/003655900750016869","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"1989_CR35","doi-asserted-by":"publisher","first-page":"16","DOI":"10.22037\/uj.v15i1.4356","volume":"15","author":"A Basiri","year":"2018","unstructured":"Basiri A, Taheri F, Taheri M (2018) The tolerability of Potassium Citrate Tablet in patients with intolerance to Potassium Citrate Powder form. Urol J 15(1):16\u201320. https:\/\/doi.org\/10.22037\/uj.v15i1.4356","journal-title":"Urol J"}],"container-title":["Urolithiasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00240-026-01989-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00240-026-01989-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00240-026-01989-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:19:34Z","timestamp":1777382374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00240-026-01989-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1007\/s00240-026-01989-0","relation":{},"ISSN":["2194-7236"],"issn-type":[{"value":"2194-7236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any disclosures to state.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of Interest Disclosure"}},{"value":"Not applicable. This study used anonymized, publicly available data from the FDA Adverse Event Reporting System (FAERS), therefore ethics approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"During the preparation of this work, the authors used AI in order to improve the readability and language of the manuscript. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted Technologies"}}],"article-number":"95"}}